Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Beats Expectations By $0.20 EPS

Voyager Therapeutics (NASDAQ:VYGR) announced its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20, Zacks reports. Voyager Therapeutics had a negative return on equity of 1.28% and a negative net margin of 2.56%. The company had revenue of $29.58 million for the quarter, compared to analysts’ expectations of $11.52 million. During the same period last year, the firm earned ($0.51) EPS.

Voyager Therapeutics Stock Down 11.1 %

Shares of NASDAQ:VYGR traded down $0.91 during trading on Wednesday, hitting $7.28. The stock had a trading volume of 283,801 shares, compared to its average volume of 684,828. Voyager Therapeutics has a 12-month low of $6.06 and a 12-month high of $11.72. The stock has a 50-day simple moving average of $8.39 and a two-hundred day simple moving average of $8.41. The stock has a market capitalization of $395.96 million, a price-to-earnings ratio of -150.77 and a beta of 0.96.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on VYGR shares. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Oppenheimer reiterated an “outperform” rating and set a $18.00 price target on shares of Voyager Therapeutics in a report on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Wednesday, July 31st. Finally, Wedbush lowered their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.83.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.